Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042004 | 0.92 | FADS1 (0.47) | FADS1TSHRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2565059 | 0.89 | FADS1 (0.54) | FADS1TSHRAPLNRPIK3CDPIK3CB | |
| SCHEMBL2566027 | 0.83 | FADS1 (0.52) | FADS1TSHRAPLNRPIK3CDPIK3CB | |
| SCHEMBL2562601 | 0.83 | FADS1 (0.51) | FADS1TSHRAPLNRPIK3CDPIK3CB | |
| SCHEMBL10042038 | 0.82 | PIK3CD (0.44) | FADS1PIK3CDPIK3CBPIK3CGPIK3CA | |
| SCHEMBL14957401 | 0.82 | PIK3CD (0.44) | FADS1PIK3CDPIK3CBPIK3CGPIK3CA | |
| SCHEMBL2560508 | 0.81 | FADS1 (0.51) | FADS1TSHRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL14957309 | 0.80 | FADS1 (0.53) | FADS1TSHRAPLNRPIK3CDPIK3CB | |
| SCHEMBL2995367 | 0.79 | FADS1 (0.54) | FADS1TSHRAPLNRPIK3CDPIK3CB | |
| SCHEMBL2558130 | 0.78 | FADS1 (0.49) | FADS1TSHRAPLNRPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023858-B2 | Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023858-B2 | Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9023858-B2 | Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| EP-2597095-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-23 | — | — | US | disclosed |
| WO-2012011591-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 武田薬品工業株式会社 (JP) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LTB4R2, LTB4R, LTC4S | FADS1 115/4885TSHR 4564/4885APLNR 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.